Avidity Biosciences (RNA) Competitors $43.65 +0.40 (+0.92%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrends RNA vs. CYTK, PTCT, CNST, ZGNX, ORIC, TEVA, BGNE, VTRS, SMMT, and MRNAShould you be buying Avidity Biosciences stock or one of its competitors? The main competitors of Avidity Biosciences include Cytokinetics (CYTK), PTC Therapeutics (PTCT), Constellation Pharmaceuticals (CNST), Zogenix (ZGNX), ORIC Pharmaceuticals (ORIC), Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Viatris (VTRS), Summit Therapeutics (SMMT), and Moderna (MRNA). These companies are all part of the "medical" sector. Avidity Biosciences vs. Cytokinetics PTC Therapeutics Constellation Pharmaceuticals Zogenix ORIC Pharmaceuticals Teva Pharmaceutical Industries BeiGene Viatris Summit Therapeutics Moderna Cytokinetics (NASDAQ:CYTK) and Avidity Biosciences (NASDAQ:RNA) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, community ranking, institutional ownership and risk. Does the MarketBeat Community prefer CYTK or RNA? Cytokinetics received 648 more outperform votes than Avidity Biosciences when rated by MarketBeat users. Likewise, 79.64% of users gave Cytokinetics an outperform vote while only 67.25% of users gave Avidity Biosciences an outperform vote. CompanyUnderperformOutperformCytokineticsOutperform Votes80279.64% Underperform Votes20520.36% Avidity BiosciencesOutperform Votes15467.25% Underperform Votes7532.75% Which has more risk & volatility, CYTK or RNA? Cytokinetics has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500. Comparatively, Avidity Biosciences has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500. Do analysts prefer CYTK or RNA? Cytokinetics presently has a consensus target price of $83.67, indicating a potential upside of 67.80%. Avidity Biosciences has a consensus target price of $63.22, indicating a potential upside of 44.84%. Given Cytokinetics' higher possible upside, analysts clearly believe Cytokinetics is more favorable than Avidity Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cytokinetics 0 Sell rating(s) 4 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.75Avidity Biosciences 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor CYTK or RNA? In the previous week, Cytokinetics had 10 more articles in the media than Avidity Biosciences. MarketBeat recorded 24 mentions for Cytokinetics and 14 mentions for Avidity Biosciences. Cytokinetics' average media sentiment score of 0.41 beat Avidity Biosciences' score of 0.38 indicating that Cytokinetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 7 Very Positive mention(s) 5 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Avidity Biosciences 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better earnings and valuation, CYTK or RNA? Avidity Biosciences has higher revenue and earnings than Cytokinetics. Avidity Biosciences is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytokinetics$7.53M781.40-$526.24M-$5.38-9.27Avidity Biosciences$9.56M544.76-$212.22M-$2.88-15.16 Is CYTK or RNA more profitable? Avidity Biosciences has a net margin of -2,772.45% compared to Cytokinetics' net margin of -17,906.25%. Cytokinetics' return on equity of 0.00% beat Avidity Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Cytokinetics-17,906.25% N/A -50.21% Avidity Biosciences -2,772.45%-27.66%-24.56% SummaryCytokinetics beats Avidity Biosciences on 9 of the 16 factors compared between the two stocks. Ad Crypto Swap Profits[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Avidity Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNA vs. The Competition Export to ExcelMetricAvidity BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.16B$6.48B$5.06B$8.89BDividend YieldN/A8.11%4.97%4.06%P/E Ratio-15.164.8389.0213.30Price / Sales544.76372.991,207.2881.01Price / CashN/A52.2739.1736.03Price / Book3.467.876.085.74Net Income-$212.22M$153.61M$119.07M$225.93M7 Day Performance-12.65%-2.00%-1.84%-1.32%1 Month Performance-6.55%-7.47%-3.65%0.60%1 Year Performance644.88%31.80%31.62%26.23% Avidity Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNAAvidity Biosciences2.3883 of 5 stars$43.65+0.9%$63.22+44.8%+631.2%$5.16B$9.56M-15.16190Insider TradeAnalyst RevisionCYTKCytokinetics4.025 of 5 stars$49.86-2.4%$83.67+67.8%+54.3%$6.03B$7.53M0.00250Analyst ForecastInsider TradeOptions VolumeNews CoveragePTCTPTC Therapeutics2.5538 of 5 stars$41.96+6.6%$42.00+0.1%+89.3%$3.04B$937.82M0.001,410Analyst DowngradeCNSTConstellation PharmaceuticalsN/A$33.99flatN/AN/A$1.63BN/A-12.10154ZGNXZogenixN/A$26.68flatN/A+0.0%$1.50B$81.69M-6.56218ORICORIC Pharmaceuticals4.1871 of 5 stars$8.74-1.7%$18.29+109.2%+22.4%$627.34MN/A0.0080Analyst RevisionTEVATeva Pharmaceutical Industries2.6924 of 5 stars$17.03+1.2%$19.67+15.5%+80.0%$19.04B$15.85B0.0037,851BGNEBeiGene3.174 of 5 stars$194.26+3.5%$247.07+27.2%+3.4%$18.92B$2.46B-23.5810,600Analyst DowngradeGap UpVTRSViatris1.3448 of 5 stars$13.13+0.6%$13.33+1.5%+38.6%$15.58B$15.43B0.0038,000SMMTSummit Therapeutics1.8653 of 5 stars$18.62-6.9%$34.75+86.6%+835.7%$14.75B$700,000.000.00105Analyst ForecastMRNAModerna4.6286 of 5 stars$36.94-0.9%$84.00+127.4%-53.2%$14.35B$6.85B0.005,600Analyst UpgradeAnalyst Revision Related Companies and Tools Related Companies Cytokinetics Competitors PTC Therapeutics Competitors Constellation Pharmaceuticals Competitors Zogenix Competitors ORIC Pharmaceuticals Competitors Teva Pharmaceutical Industries Competitors BeiGene Competitors Viatris Competitors Summit Therapeutics Competitors Moderna Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RNA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avidity Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avidity Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
